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Cancer genomics has focused on the discovery of mutations and chromosomal structural rearrangements that
either increase susceptibility to cancer or support the cancer phenotype. Protein kinases are the most frequently
mutated genes in the cancer genome, making them attractive therapeutic targets for drug design. However, the
use of some of the kinase inhibitors (KIs) has been associated with toxicities to the heart and vasculature, in-
cluding acute coronary syndromes and heart failure. Herein we discuss the genetic basis of cancer, focusing on
mutations in the kinase genome (kinome) that lead to tumorigenesis. This will allow an understanding of the
real and potential power of modern cancer therapeutics. The underlying mechanisms that drive the cardiotoxicity
of the KIs are also examined. The preclinical models for predicting cardiotoxicity, including induced pluripotent
stem cells and zebrafish, are reviewed, with the hope of eventually being able to identify problematic agents
before their use in patients. Finally, the use of biomarkers in the clinic is discussed, and newer strategies (i.e.,
metabolomics and enhanced imaging strategies) that may allow earlier and more accurate detection of cardio-
toxicity are reviewed. (J Am Coll Cardiol 2013;61:267–74) © 2013 by the American College of Cardiology
Foundation
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cardiology” seems to be growing at a rapid pace, driven at
least in part by the fact that cancer patients typically have
cardiovascular disease and vice versa, demanding a team
approach. Another driver of this apparent boom in interest
is the increasing awareness of the toxicities, in particular
cardiac toxicities, associated with cancer therapeutics. Ini-
tially centered on anthracycline- and trastuzumab-induced
cardiotoxicity, similar issues are now being faced with some
of the so-called “targeted therapeutics,” which largely target
protein kinases that are activated or overexpressed, and thus
drive growth of various cancers (1,2).
Nearly one-half of the 518 protein kinases encoded by the
human genome are expressed from loci associated with
specific diseases or regions amplified in human cancers (3).
Furthermore, kinases are the most frequently mutated genes
in the cancer genome, making them attractive therapeutic
targets for drug design. Indeed, these targeted therapeutics
have radically altered approaches to the treatment of a
number of cancers and now dominate drug discovery and
development. Targeted anticancer drugs were initially
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Manuscript received May 14, 2012; accepted May 29, 2012.thought to affect tumors but not normal tissue in which
kinases were not constitutively active. Thus, the hope of
targeted therapy was one of high efficacy, with minimal
adverse effects compared with traditional chemotherapy.
However, unexpected reports of cardiotoxicity from ap-
proved targeted drugs suggest that these agents are not
magic bullets (4). In fact, as long as a kinase maintained
expression in the heart, targeting that kinase in cancer
could, theoretically, cause cardiotoxicity. Indeed, there
are numerous overlapping signaling pathways that drive
tumorigenesis but that are also required for cardiomyo-
cyte survival or function (Fig. 1). Cardiotoxicity with
kinase inhibitors (KIs) could be said to occur “predict-
ably” if a given molecular target participates in 1 basic
cardiac function.
The cardio-oncologist also needs to understand cancer
and its biology. Central to cancer management is the
understanding of cancer as the cumulative phenotypic con-
sequence of acquired genetic and epigenetic alterations in
cancer cells. Herein, we also highlight recent advances in
cancer genetics and genomics that convey the potential of
this discipline to drive personalized cancer medicine. This
review also illustrates the importance of defining the bio-
logical relevance of genomic data as a key step in realizing
the full clinical potential of developing better drugs for
cancer management with minimal cardiotoxicity. The rapid
emergence of genome technology allows the complete
molecular profiling of a patient’s tumor. Kinome-wide
screening, combined with kinase-targeted libraries of small
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structure determination should
allow the discovery of selective
molecules that will further vali-
date kinases as key targets in
oncology (5). This approach
should also advance our rather
limited understanding of the role
that those kinases which are ex-
pressed in the human heart play
in cardiac biology.
We are entering a new era, one
in which personalized medicine
in cancer patients is becoming a
reality. The success of drug de-
velopment in cancer, while lim-
iting cardiotoxicity, will require a
multidisciplinary approach, with
collaborations between oncolo-
gists, cardiologists, pharmacolo-
gists, and toxicologists, as well as a strong commitment
from industry and the regulatory agencies to ongoing
translational research. This evolving discipline demands that
cardiotoxicity be considered, both in preclinical and clinical
scenarios. This issue should be foremost in the mind of
investigators during protocol development, enrollment, and
follow-up. This should also include postapproval surveil-
lance of patients treated with these drugs for it is then that
problems will likely appear when patients with significant
comorbidities begin to use these agents. Because small
molecule KIs are believed to be the foundation of future
cancer treatments, researchers with a particular expertise in
this field will be required. Fortunately, there seems to be a
growing interest in cardio-oncology at the basic, clinical,
and funding agency level (National Cancer Institute and
National Heart, Lung, and Blood Institute) and that leads
to optimism.
What Do We Know and Do Not Know: Guidelines
Although general guidelines exist for the treatment and
follow-up of patients receiving anthracyclines and, to some
extent, trastuzumab (Herceptin), that is not the case with
the targeted therapeutics (predominantly KIs). This is
due in part to the fact that KIs are often unique, with
unique targets and, therefore, unique toxicities. To date,
we are aware of only 3 attempts to generate guidelines for
the care of cancer patients receiving targeted therapeu-
tics. The first was a working group sponsored by the Heart
Failure Association of the European Society of Cardiology
(6). Although the document focused primarily on anthra-
cyclines and trastuzumab, it was a valiant attempt to try to
highlight the gaps in knowledge concerning targeted ther-
apeutics and to begin to address these gaps. Most impor-
tantly, the document highlighted how little is understood
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endothelial growth factorabout the KIs, including the very limited data on theircardiac toxicities. In addition, they noted the need for
preclinical screening strategies and also addressed the
potential use of biomarkers of injury, specifically tro-
ponins and B-type natriuretic peptide, although there
were (and continue to be) very little data on the use of
these agents in patients being treated with KIs; the
exception is some work conducted with trastuzumab (7).
This working group was also the first to address the class
of agents that are particularly problematic: the antiangio-
genesis agents (sunitinib and sorafenib). It was also
suggested that registries should be used for potentially
problematic agents. Finally, this group formulated several
recommendations for patient care as well as guides for the
design of future clinical trials. This reasoned and bal-
anced document is very much worth reading.
After the publication of this paper and the clear docu-
mentation of cardiotoxicity with some KIs (8,9), the Na-
tional Cancer Institute convened 2 panels: 1 to address the
hypertension that can be profound with antiangiogenesis
agents and the other to address cardiotoxicity (10,11). These
working groups were specifically charged with developing
guidelines for the management of patients who were en-
rolled in clinical trials sponsored by the National Cancer
Institute. Both panels developed general management strat-
egies, although we think it is fair to say that there was
serious debate surrounding the cardiotoxicity guidelines.
This debate is to be expected when 2 disciplines, both of
which want the best for the patient, realize that their
strategies are at cross-purposes. This cognitive dissonance is
at the core of why cardio-oncology will be such an impor-
tant discipline going forward. In summary, much remains to
be learned about targeted therapeutics and their use, and
only when we have a better understanding of them both in
cancers and in the heart and vasculature can true guidelines
be generated.
The Genetic Basis of Cancer
Cancer is a genetic disease. The cancer cell arises as a clone
that expands in an unregulated fashion, driven in part by
sequential accumulation of mutations (12,13). Thus, all
cancers arise as a result of changes in the DNA sequence of
the genomes of cancer cells (14).
The first consistent genetic abnormality associated with
human cancer was the translocation that created the Phil-
adelphia chromosome, leading to a fusion of 2 protein
kinases, breakpoint cluster region and Abelson leukemia
virus tyrosine kinase (ABL), in chronic myeloid leukemia
(CML) (15). This led to constitutive activation of the ABL
kinase that promoted immortality in myeloid progenitor
cells in the bone marrow, which leads to the leukemia.
However, because no consistent chromosomal alterations
were found in other forms of cancer, it was thought that
chromosome alterations were a result of cancer, not a cause.
In 1976, however, Stehelin et al. (16) demonstrated that
oncogenes (i.e., genes that participate in the initiation of
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A-2 viral oncogene homolog (SRC), had nontransforming
counterparts (proto-oncogenes) that were expressed in nor-
mal cells. This work helped to establish the role of genetic
alterations in initiating tumorigenesis rather than arising as
a result of tumorigenesis (17). Thus, SRC became the first
human proto-oncogene to be identified, and many more
proto-oncogenes were discovered soon after. Finally, it was
demonstrated that introduction of total genomic DNA from
human cancers into phenotypically normal (NIH3T3) cells
could convert them into cancer cells (18,19).
Somatic Genetic Alterations and
Cancer Development
All cancers arise as a result of somatically acquired changes
in the DNA (17,20). This does not mean, however, that all
of the somatic abnormalities present in a cancer genome are
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became recognized as key mediators of the cancer phe-
notype (12,14). Collectively, they result in the activation
or inhibition of various biological events involved in
cancer pathophysiology, including angiogenesis, metasta-
sis, and altered cell growth (22).
Somatic mutations tend to be randomly distributed
throughout the genome and may be classified as “driver” or
“passenger” mutations (20,22). A driver mutation is causally
implicated in oncogenesis because it confers a growth
advantage to the cells. Cancer cells expand, invade into
surrounding tissue, and typically metastasize. The number
of driver mutations in a cancer cell reflects the number of
mutated cancer genes and thus drives the cell biological
processes required to convert a normal cell into a cancer
clone (17,20). The remaining mutations are passengers and
do not contribute to cancer development. Passenger muta-
tions are found within cancer genomes because somatic
mutations without functional consequences often occur
during cell division. A cell that acquires a driver mutation
will already have biologically inert somatic mutations within
its genome (13). Thus, the catalog of somatic mutations in
the genome of a cancer cell represents genomic changes that
usually accumulate over several decades (12,23,24). There
are usually between 1,000 and 10,000 somatic mutations in
the genome of adult cancers (12,20,25). Catalogue of
Somatic Mutations in Cancer is currently the most com-
prehensive resource for information on somatic mutations in
human cancer. Almost 4,800 genes and 250,000 tumors
have been examined, resulting in 50,000 mutations being
available for investigation (24).
Genome-Wide Approaches
for Cancer Gene Discovery
The emergence of the human genome sequence advanced
the study of cancer genomes in many ways. It led to a
fundamental shift toward global views of genomes and
transcriptomes in human biology and disease. This progress
was made possible by increasingly powerful technologies. By
the late 1990s, microarray applications and high-throughput
sequencing began to explore entire cancer genomes
(12,21,26). These advances, together with advances in
bioinformatics, enabled a link between tumor genomic
alterations and critical functional roles in cancers (21).
These ongoing global genome characterizations are revolu-
tionizing cancer biology and management. The goal of the
Cancer Genome Atlas is to catalog and discover major
cancer-causing genome alterations in large cohorts of hu-
man tumors. The International Cancer Genome Consor-
tium has similar goals, with 39 teams planning to study
18,000 tumor genomes in 50 different cancers (25). It is
strikingly apparent that the researchers in cardiovascular
disease need similar initiatives.
Second-generation DNA sequencing technologies and
their application to cancer have accelerated the pace ofinvestigations of cancer genomes (27,28), enabling the
complete (and efficient) sequencing of entire genomes (27).
One key advantage is that second-generation sequencing
offers structural information never before available, allowing
assessment of chromosomal rearrangements in cancer
(23,27). These technologies have allowed sequencing of
2,000 individual cancers (12).
The Cancer Kinome and its “Druggability”
The kinome of an organism is the set of protein kinases in
its genome. The term was first used in 2002 in a report
analyzing the 518 human protein kinases (1). Kinases are
enzymes that catalyze phosphorylation of amino acids and
are grouped into 3 major families: kinases that phosphory-
late the amino acids serine and threonine, those that
phosphorylate tyrosine, and some that can phosphorylate
both. Approximately 90 of the 518 kinases in the human
kinome are tyrosine kinases (3). Since the discovery of the
first oncogene, vSrc, in the 1970s and its identification as an
enzyme with tyrosine kinase activity (29,30), dysfunctional
signaling by mutated or overexpressed kinases has been
intimately linked to cancer (31). There are numerous
oncogenes, many of which are protein kinases (17). Protein
kinases may act as tumor suppressors or proto-oncogenes in
normal, healthy cells, but mutations in these may lead to
tumorigenesis through inactivation of a tumor suppressor or
constitutive activation of a proto-oncogene, transforming it
into an oncogene. The approval of the first KI, imatinib, for
the treatment of CML in 2001 and the success of antibody-
based drugs that targeted the epidermal growth factor
receptor (HER2) in breast cancer (trastuzumab) and colon
cancer (cetuximab) heralded the current period of KI devel-
opment (5). More than 10,000 patent applications for KIs
having been filed since 2001 in the United States alone. To
date, approximately 80 KIs have progressed to the point of
clinical evaluation and 13 KIs have been approved for cancer
treatment (32) (Table 1).
Genetic Alterations in the Kinome and Cancer
Kinases and their direct regulators are the most frequently
mutated oncogenes and tumor suppressors (17,25,33). The
MoKCa database (Mutations of Kinases in Cancer) was
developed to annotate, and predict, the phenotypic conse-
quences of mutations in protein kinases implicated in cancer
(34). Recent resequencing of the kinome in cancer cell lines
has revealed that most somatic mutations are likely to be
passengers (20). Although difficult, differentiating passen-
gers from drivers is critical for understanding the molecular
mechanisms responsible for tumor initiation and progres-
sion and also provides prognostic information as well as
targets for therapeutic intervention (35).
acute
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KIs as Anticancer Agents
Many human malignancies are linked with activated kinases
or inactivated phosphatases, and one third of the targets
under investigation by pharmaceutical companies are ki-
nases (36). Two classes of therapeutics have been developed
to target the cancer kinome: humanized monoclonal anti-
bodies (mAbs) and KIs. The mAbs bind cancer cell–specific
antigens, commonly to the extracellular portion of receptor
tyrosine kinases, thereby inhibiting tyrosine kinase activa-
tion. The binding of mAbs to the extracellular domain of
the receptor tyrosine kinase can block ligand binding to the
receptor and inhibit subsequent dimerization and activation
of the kinase (37,38). Trastuzumab (Herceptin) binds the
HER2 receptor, but other mAbs bind the growth factors
that activate the receptors. For example, bevacizumab
(Avastin) targets vascular endothelial growth factor (VEGF)
A, preventing it from interacting with the VEGF receptor
and leading to inhibition of tumor angiogenesis (37).
The dependency of certain cancers on 1 or a few genes for
maintenance of the malignant phenotype, termed onco-
genes addiction, provides a strong rationale for molecular
targeting in cancer therapy. KIs have revolutionized the
treatment of select cancers, such as CML and gastrointes-
tinal stromal tumor, which are driven by a single oncogenic
kinase. For these conditions, in most cases, KIs have led to
multiyear increases in survival (39). One other issue involves
acquired resistance to KIs. This resistance is typically due to
de novo mutations in the kinase that reduce binding affinity
of the drug to the kinase. In some cases, it has been possible
Clinically Approved Kinase-Targeted Oncology AgentsTable 1 Clinically Approved Kinase-Targeted Oncology Agents
Drugs (Trade Name) Company Year of Approval Prim
Sirolimus (Rapamune) Pfizer 2000 mTOR
Imatinib (Gleevec) Novartis 2001 BCR-AB
Gefitinib (Iressa) AstraZeneca 2003 EGFR
Erlotinib (Tarceva) Roche/Genentech 2004 EGFR
Sorafenib (Nexavar) Bayer 2005 RAF-1/
VEG
Dasatinib (Sprycel) Bristol-Myers Squibb 2006 BCR-AB
Sunitinib (Sutent) Pfizer 2006 PDGFR
Lapatinib (Tykerb) GlaxoSmithKline 2007 EGFR (
HER
Nilotinib (Tasigna) Novartis 2007 BCR-AB
Temsirolimus (Torisel) Pfizer 2007 mTOR
Pazopanib (Votrient) GlaxoSmithKline 2009 PDGFR
Everolimus (Afinitor) Novartis 2009 mTOR
Axitinib (Inlyta) Pfizer 2012 VEGFRs
ALL  acute lymphoblastic leukemia; BCR-ABL  breakpoint cluster region–Abelson leukemia v
DDR1 discoidin domain receptor 1; EGFR epidermal growth factor receptor; FLT3 FMS-like ty
(ERBB2 in mice); IRM  imatinib-resistant ABL mutants; mTOR  mammalian target of rapamyc
PDGFR  platelet-derived growth factor receptor; Ph ALL  Philadelphia chromosome-positive
ET  rearranged during transfection; SEGA  subependymal giant cell astrocytoma; SRC  Schto address this problem with redesign of the inhibitor; forexample, the second-generation breakpoint cluster region–
ABL KIs dasatinib and nilotinib.
Critical to the activity of the kinase is adenosine triphos-
phate (ATP) binding in the cleft within the kinase “hinge”
(32). The ATP cleft contains structural elements responsi-
ble for the catalytic activity of the kinase. All kinases have a
conserved A loop, and this region is the target of most KIs
in use or in development (33).
On the basis of the mode of binding to kinases, KIs can be
classified into 4 different types (Table 2). Type I inhibitors
constitute the majority of ATP-competitive inhibitors and
recognize the active conformation of the kinase (32,36). Be-
cause the structure of the ATP pocket is highly conserved
across the human kinome, it is relatively easy to make an
inhibitor that targets the ATP pocket of the kinase of interest.
Due to this, most KIs discovered to date are ATP-competitive
inhibitors. However, it is not surprising that lack of selectivity
is an issue with most of the inhibitors in this class (38). By
contrast, the type II inhibitors recognize the inactive confor-
mation of the kinase and still have contacts to the ATP pocket,
but they also interact with a site adjacent to the pocket. This
action allows enhanced selectivity and binding to the inactive
confirmation. These KIs are typically more potent than the
type I inhibitors (32,36). Type III inhibitors (non–ATP-
competitive inhibitors) bind to regions remote from the ATP
pocket. Inhibitors in this class tend to exhibit the highest
degree of selectivity because they exploit binding sites and
regulatory mechanisms unique to a particular kinase. However,
lack of structural information for these regions represents a
major hurdle in designing inhibitors (32,40). A fourth class
(covalent inhibitors) is capable of forming an irreversible,
Targets
Representative Malignanciesarget(s) Relevant Others
NI RCC
ABL, c-KIT, DDR1,
PDGFRs
GIST, CML, Ph ALL
NI Gliomas, NSCLC
NI Gliomas, NSCLC, pancreatic cancer
PDGFR, c-KIT, FLT3 RCC, hepatocellular carcinoma
most IRMs c-KIT, ABL, SRC, PDGFRs Imatinib-resistant CML, ALL, GIST
FRs, c-KIT RET, FLT3, CSF-1R RCC, GIST, PNET
),
B2)
NI HER2 breast cancer, ovarian
cancer, gliomas, NSCLC
most IRMs c-KIT, ABL, PDGFRs Imatinib-resistant CML, ALL, GIST
NI RCC
FRs, c-KIT NI RCC
NI RCC, PNET, SEGA
FRs, c-KIT NI RCC
osine kinase; CML  chronic myeloid leukemia; CSF-1R  colony-stimulating factor 1 receptor;
kinase 3; GIST gastrointestinal stromal tumor; HER2 human epidermal growth factor receptor
none identified; NSCLC  non–small-cell lung cancer; RAF  rapidly accelerated fibrosarcoma;
lymphocytic leukemia; PNET  pancreatic neuroendocrine tumors; RCC  renal cell carcinoma;
ppin A-2 viral oncogene homolog; VEGFR  vascular endothelial growth factor receptor.ary T
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EGFR signaling even in gefitinib-resistant cell lines
(harboring a T790M mutation). Therefore, tyrosine ki-
nase inhibitors may overcome resistance associated with
mutations such as T790M (41). A number of these
new-generation TKIs have been developed (41). Despite
the large number of kinases that could be targeted by this
approach, there are concerns about the potential for toxicity of
covalent inhibitors as a result of permanent modification of
unanticipated targets or even permanent systemic inhibition
of anticipated targets.
Molecular Mechanisms of Cardiotoxicity
The first report of cardiotoxicity with tyrosine kinase inhib-
itors was a case series of 10 patients who developed
congestive heart failure while receiving imatinib (8). Subse-
quently, much more serious toxicity was identified with
other molecularly targeted therapies. There are 2 general
types of cardiotoxicity: on-target and off-target.
On-target toxicity. With on-target toxicity, the kinase that
is targeted in the cancer also provides an important function
in the heart and/or vasculature (38). Inhibiting this kinase
leads to adverse consequences in the heart. An example of
this is sorafenib. In addition to inhibiting several growth
factor receptors, sorafenib inhibits rapidly accelerated fibro-
sarcoma (RAF)-1 and BRAF. RAF family kinases function
in the pro-survival ERK (or mitogen-activated protein
kinase) cascade. The importance of RAF-1 in the heart has
been demonstrated in mouse models in which conditional
cardiac-specific deletion of RAF-1 resulted in left ventric-
ular (LV) dilation and reduced contractile function (42).
Escudier et al. (43) demonstrated the efficacy of sorafenib in
advanced clear-cell carcinoma (kidney). Cardiotoxicity was
observed in the form of cardiac ischemia or infarction
(reported to occur in 3% of patients) (38). We and others
have observed cases of probable sorafenib-induced LV
dysfunction and heart failure, but we do not know the rate
of these events because careful studies examining this
question have not been done.
Approaches to deal with unavoidable on-target toxicity
have been proposed and include targeted delivery of drug
specifically to the cancer, sparing normal tissue, or inhibit-
ing cell death pathways in the heart that are activated by a
Classification of Kinase InhibitorsTable 2 Classification of Kinase Inhibitors
Factor Type 1 Type 2
Target of binding ATP pocket ATP pocket and adjac
pocket
Type of binding Noncovalent Non-covalent
Mode of action ATP-competitive ATP-competitive
Examples Sunitinib and dasatinib Sorafenib and imatini
ATP  adenosine triphosphate.compound but that are not necessary for tumor cell death. fFor the latter, JNK inhibition has been proposed as a
strategy to limit imatinib-induced cardiomyocyte death
without reducing antitumor efficacy (44). Another approach
could be to identify and target unique kinases from the
cancer kinome that are either not expressed in the heart or
are not required for normal heart function. So far, target
selection in drug discovery has been strongly biased toward
previously validated targets. It seems that the majority of
agents in development target kinases for which approved
drugs are already available. Recently, novel kinase targets
that are uncharacterized have been identified via genome
sequencing and ribonucleic acid interference screens (5).
Off-target toxicity. Off-target toxicity is directly related to
nonselectivity. In this scenario, inhibition of a target not
intended to be inhibited by a KI is responsible for the
cardiotoxicity. Almost all of the approved KIs bind to
multiple kinases, although with different affinities. Cardio-
toxicity with KIs is directly correlated with a lack of target
specificity (45). Often, the kinase mediating the toxicity will
not be known, and the complexity of identifying the key
target, inhibition of which leads to cardiotoxicity, can be
very challenging. This is the main reason that we believe
enhanced selectivity of KIs should be a goal.
An example of the problem with poor selectivity is
sunitinib-induced cardiotoxicity. Sunitinib was designed as
a multikinase inhibitor that targeted VEGF receptor 1,
platelet-derived growth factor, colony-stimulating factor 1
receptor, and several others. However, it seems that, at
therapeutic plasma levels, sunitinib would inhibit approxi-
mately 90 kinases (46). The reported incidence of cardio-
toxicity (primarily LV dysfunction) with sunitinib was low
in the early clinical trials. However, a more thorough
retrospective review of data reported in Chu et al. (51) in a
tudy of 75 patients with gastrointestinal stromal tumor
ound an 8% incidence of heart failure and a 28% incidence
f LV ejection fraction decrease of 10%.
Toxicity of sunitinib is likely due to both on- and
ff-target effects. Off-target cardiotoxicity could be avoided
or reduced) by improving selectivity and/or redesigning the
rug so that it no longer inhibits the crucial kinase (assum-
ng the kinase does not play a key part in cancer progres-
ion). Obviously, off-target toxicity will be much more
Type 3
(Allosteric Inhibitors)
Type 4
(Covalent Inhibitors)
Remote from ATP pocket Kinase active site
Noncovalent Covalent
Non–ATP-competitive Irreversibly or reversibly blocks ATP
binding to kinase
PD98059 and U0126 Wortmannin (LY94002) and
PD168393ent to
brequent with multitargeted KIs and combination therapy.
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Our limited understanding of the role various kinases play in
the heart makes it impossible, at least at this point in time,
to predict which KIs will have a high probability of
associated cardiotoxicity. Therefore, it is essential that valid
preclinical models be developed. That said, it is our sense
that most models, including rodents, are relatively insensi-
tive, due at least in part to the lack of comorbidities such as
hypertension and coronary artery disease in these animals
(47). Cancer patients typically have cardiovascular comor-
bidities, and inhibition of protective signaling pathways by
KIs, which would be well tolerated in the rodent, might not
be in patients who have cardiovascular disease. Underscor-
ing the importance of comorbidities was a study, albeit
small, which identified the presence of coronary artery
disease as the best predictor of cardiotoxicity with the KI
sunitinib (9). Similarly, sunitinib can cause striking hyper-
tension in patients yet we saw only mild hypertension in
mice. Strategies to stress the heart, such as thoracic aortic
constriction or infusion of pressors, will induce hyperten-
sion, but these are costly and time-consuming procedures
that are technically very demanding (at least with thoracic
aortic constriction).
As a result, investigators have searched for alternatives.
Zebrafish have been successfully used to screen for drugs
that might prolong QT intervals. Cheng et al. (48) used
ebrafish in an attempt to identify agents that might be
ardiotoxic; they were able to detect cardiotoxicity with
unitinib and sorafenib based on quantification of contrac-
ile dysfunction. They also used a transgenic fish that
xpresses a red fluorescent protein in cardiomyocytes and
ere able to determine that both drugs led to a reduction in
otal cardiomyocyte number. More surprisingly, they were
ble to interrogate signaling pathways that were disrupted in
he drug-treated fish and to identify a cardioprotective
athway that preserved ventricular function. The next step
ould be to use the so-called Casper fish that, unlike
ild-type zebrafish, remains translucent throughout life.
hus, LV function can be examined over time in the adult
sh, eliminating drug-induced toxicity as a result of devel-
pmental effects.
Recent advances in the development and production of
tem cell–derived cardiomyocytes has allowed an assessment
f this model to study cardiac arrhythmia and prediction of
ardiotoxicity (49). Human stem cell–derived cardiomyo-
ytes exhibit consistent rhythmic contractions, and pro-
onged culture increasingly promotes the expression of adult
ardiac proteins (50,51). In addition, studies using these
tem cell–derived cardiomyocytes helped investigate the
ole for sunitinib in inducing cardiac arrhythmia and car-
iotoxicity, as well as the potential role for 2 kinases,
MPK and RSK, which have been speculated to modulates
hese toxicities (52). Although generic cytotoxicity observed
n cells in vitro has been questioned as a reliable predictor of
rgan toxicity (53), the persistent rhythmic beating of stemell–derived cardiomyocytes provides a unique mechanistic
dvantage in studying changes in cardiomyocyte function,
ontraction, and energy homeostasis that occur during
I-mediated cardiotoxicity.
linical Detection of Cardiotoxicity:
iomarkers and Imaging
lthough significant strides have been made in identifying
iomarkers, including troponin I (the most studied), that
redict cardiotoxicity with anthracyclines, much less is
nown about the use of biomarkers in the setting of KI
reatment. The only work that we are aware of is with the
Ab trastuzumab (7). Thus, it is entirely unclear whether
hese “traditional” biomarkers will be effective in KI-
nduced cardiotoxicity. We suspect that better biomarkers
ill be needed to detect toxicity with the KIs, and we
ropose that more sensitive metabolomic strategies should
e developed along the lines of the work done by Gerszten
t al. (54).
As for imaging, encouraging results in patients treated
ith anthracyclines and trastuzumab have been reported
ith a combination of longitudinal strain and high-
ensitivity troponin I (55). It remains to be seen whether
his approach will be useful in the “KI-alone” treated
atients.
onclusions and Future Directions
argeted therapeutics, particularly KIs, have radically al-
ered cancer treatment. However, given the central role
layed by kinases in the heart and other organs (leading to
n-target toxicity with KIs), the relatively poor selectivity of
he current (and future) crop of KIs, leading to off-target
ffects, the paucity of verified preclinical models to predict
oxicity, the uncertainties as to how effective traditional
iomarkers and imaging will be in identifying cardiotoxicity
ith these agents, our poor understanding of the role played
y the majority of kinases expressed in the heart, and the
umber of new KIs in development, we are heading into
ncharted waters.
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